RxDoctor Payments Data

Todd Maus, MD

Ophthalmology · Lakewood, CONPI 1437134038

Payments from drug & device makers

$1,718in general payments, 2019–2025

Across 61 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$301
  • Alcon$280
  • Sight Sciences, Inc.$202
  • Carl Zeiss Meditec, Inc.$181
  • Carl Zeiss Meditec USA, Inc.$151
  • AbbVie$142
  • plus $461 from 10 others

What the payments were for

  • Food & beverage$1,67898%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,718 in reported general payments places this provider in the 60th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$322,516
Medicare patients
779
Services billed
2,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost90$55,314
RestasisCyclosporine15$19,681
Latanoprost1,214$16,778
VyzultaLatanoprostene Bunod16$9,719
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat581$9,692
Dorzolamide-TimololDorzolamide/Timolol/Pf41$7,427
CombiganBrimonidine Tartrate/Timolol15$5,823
TafluprostTafluprost/Pf18$5,745
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$5,230
Timolol Maleate486$4,918
Prednisolone Acetate83$4,691
SimbrinzaBrinzolamide/Brimonidine Tart11$4,382
Travoprost29$3,990
Alphagan PBrimonidine Tartrate15$3,340
Brimonidine Tartrate57$2,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$142$84,157135 claims
Bausch & Lomb Americas Inc.Vyzulta$16$9,71916 claims
AlconSimbrinza$280$4,38211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →